YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Empire State Realty Trust (NYSE: ESRT [https://seekingalpha.com/symbol/ESRT]) announced on Monday that it signed [https://seekingalpha.com/pr/20588701-empire-state-realty-trust-signs-26134-square-foot-space-with-instacart-at-111-w-33rd-s…
* Hansa Biopharma press release [https://seekingalpha.com/pr/20395181-hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results] (HNSBF [https://seekingalpha.com/symbol/HNSBF]): Q4 GAAP EPS loss of SEK1.62 * Revenue of SE…
LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sa…
* Hansa Biopharma press release [https://seekingalpha.com/pr/20168962-hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results] (OTC:HNSBF [https://seekingalpha.com/symbol/HNSBF]): Q2 GAAP EPS of -SEK 2.53. *…
LUND, Sweden, July 8, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Re…
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa's lead candidate…
Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care LUND, Sweden, Dec. 14, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (…
LUND, Sweden, Dec. 13, 2023 /PRNewswire/ -- Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 29, 2023 and has the following…
LUND, Sweden, Dec. 7, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when admi…
LUND, Sweden, Dec. 5, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), announced today that it plans to restructure the organisation to better align and focus on key clinical development and commercial priorities. Th…
• Encouraging high-level results for first-in-human trial of HNSA-5487• Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences • Dr. Hitto Kaufmann appointed new CSO LUND, Sweden, Oct. 26, 2023 /PRNewswire/ -…
LUND, Sweden, Oct. 17, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results from an extended pooled analysis using data from the 1…
Biologic License Application submission expected for 2025 LUND, Sweden, Oct. 11, 2023 /PRNewswire/ — Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced rando…
HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rar…
LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Sc…
LUND, Sweden, July 31, 2023 /PRNewswire/ -- Hansa Biopharma AB "Hansa" or the "Company", (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the number of outstanding votes in Han…
Solid product sales in Q2 2023 Collaboration announced in gene therapy with Genethon in Crigler-Najjar syndrome New Eurotransplant desensitization program implemented in June First patient treated in new investigator-initiated Phase 2 stud…
LUND, Sweden, July 19, 2023 /PRNewswire/ -- Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced first patient treated with imlifidase in an investigator-initiated phase 2 study in an…
Regulatory milestone marks the first time Idefirix has been approved in kidney transplantation from both living and deceased donors LUND, Sweden, July 11, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in…
LUND, Sweden, July 4, 2023 /PRNewswire/ -- Hansa Biopharma AB (publ.) (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announces today that, in accordance with chapter 4, 6§ of the Swedish Annual…
LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained reimbursement in Belgium for its first-in-…
LUND, Sweden, May 30, 2023 /PRNewswire/ -- Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pi…
LUND, Sweden and EVRY, France, April 27, 2023 /PRNewswire/ -- Hansa Biopharma AB, "Hansa", (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy res…
Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-5487: Phase 1 clinical study started in h…
LUND, Sweden, March 29, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that the Spanish Minister of Health (Ministerio de Sanidad) h…
LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March…
Total 2022 revenue of SEK 155m Cash runway extended into 2025 Market Access obtained in four of the five largest European markets Reported positive Phase 2 top-line data in AMR Decision made to initiate clinical study with imlifidase as a…
Idefirix® is the first and only product approved for use in highly sensitized patients waiting for a kidney transplant in the Czech Republic1,2 Availability of Idefirix® for eligible highly sensitized patients to begin January 1, 2023 LUND…
LUND, Sweden, Dec. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB "Hansa" or the "Company", (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Company's registered share capita…
LUND, Sweden, Dec. 23, 2022 /PRNewswire/ -- Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 30, 2022 and has the following…
Idefirix® is granted full access and reimbursement in line with the indication approved by the European Medicines Agency (EMA).1 The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the oppor…
Data readout demonstrates a significantly superior capacity of imlifidase to rapidly reduce levels of donor-specific antibodies (DSAs) compared to plasma exchange (standard of care) in the five days following the start of the treatment. A…
The clinical study will evaluate imlifidase as pre-treatment in patients with pre-existing IgG antibodies to Sarepta's SRP-9001, an investigational AAV-based gene therapy for the treatment of DMD DMD is an irreversible, progressive disease…
Total Revenue of SEK 67m in the third quarter 2022 Positive reimbursement decisions received in Poland and Scotland $70 million raised in non-dilutive financing Imlifidase included in ESOT guidelines published in Transplant International L…
LUND, Sweden, Sept. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB "Hansa" or the "Company", (NASDAQ Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the Company's registered share capita…
LUND, Sweden, Sept. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022. All interested parties are invited to participate in a tel…